ATE556061T1 - Therapeutisches oder prophylaktisches mittel gegen multiple sklerose - Google Patents

Therapeutisches oder prophylaktisches mittel gegen multiple sklerose

Info

Publication number: ATE556061T1
Authority: AT; Austria
Prior art keywords: therapeutic; prophylactic agent; multiple sclerosis; agent against; against multiple
Prior art date: 2006-06-19

Application number

AT07745470T

Other languages

English (en)

Inventor

Mie Kaino

Kenichi Hayashi

Hiroyuki Meguro

Original Assignee

Toray Industries

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-19

Filing date

2007-06-18

Publication date

2012-05-15

2007-06-18 Application filed by Toray Industries filed Critical Toray Industries

2012-05-15 Application granted granted Critical

2012-05-15 Publication of ATE556061T1 publication Critical patent/ATE556061T1/de

Links

230000000069 prophylactic effect Effects 0.000 title abstract 5
230000001225 therapeutic effect Effects 0.000 title abstract 5
201000006417 multiple sclerosis Diseases 0.000 title 1
229940124364 agent for multiple sclerosis Drugs 0.000 abstract 2
FSWQDGFGEMMROI-ZZXKWVIFSA-N (e)-2-[(2,6-dichlorobenzoyl)amino]-5-[4-[propan-2-yl(pyrimidin-2-yl)amino]phenyl]pent-4-enoic acid Chemical compound N=1C=CC=NC=1N(C(C)C)C(C=C1)=CC=C1\C=C\CC(C(O)=O)NC(=O)C1=C(Cl)C=CC=C1Cl FSWQDGFGEMMROI-ZZXKWVIFSA-N 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
150000002332 glycine derivatives Chemical class 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
239000004615 ingredient Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/85—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic unsaturated carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D309/06—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/04—Seven-membered rings not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrane Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT07745470T 2006-06-19 2007-06-18 Therapeutisches oder prophylaktisches mittel gegen multiple sklerose ATE556061T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2006168387		2006-06-19
PCT/JP2007/062220 WO2007148648A1 (ja)	2006-06-19	2007-06-18	多発性硬化症の治療又は予防剤

Publications (1)

Publication Number	Publication Date
ATE556061T1 true ATE556061T1 (de)	2012-05-15

Family

ID=38833390

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07745470T ATE556061T1 (de)	2006-06-19	2007-06-18	Therapeutisches oder prophylaktisches mittel gegen multiple sklerose

Country Status (10)

Country	Link
US (1)	US7879837B2 (de)
EP (1)	EP2039687B1 (de)
JP (1)	JP5228911B2 (de)
KR (1)	KR101423347B1 (de)
CN (1)	CN101472900B (de)
AT (1)	ATE556061T1 (de)
AU (1)	AU2007262147B2 (de)
CA (1)	CA2655573C (de)
ES (1)	ES2384400T3 (de)
WO (1)	WO2007148648A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR059898A1 (es)	2006-03-15	2008-05-07	Janssen Pharmaceutica Nv	Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en)	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
SI2203439T1 (sl)	2007-09-14	2011-05-31	Ortho Mcneil Janssen Pharm	1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
ES2409215T3 (es)	2007-09-14	2013-06-25	Janssen Pharmaceuticals, Inc.	4-fenil-1H-piridin-2-onas 1-3-disustituidas
BRPI0817101A2 (pt)	2007-09-14	2017-05-09	Addex Pharmaceuticals Sa	4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas
ES2637794T3 (es)	2007-11-14	2017-10-17	Janssen Pharmaceuticals, Inc.	Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
ES2439291T3 (es)	2008-09-02	2014-01-22	Janssen Pharmaceuticals, Inc.	Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
CA2738849C (en)	2008-10-16	2016-06-28	Addex Pharma S.A.	Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
ES2401691T3 (es)	2008-11-28	2013-04-23	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
SG176018A1 (en)	2009-05-12	2011-12-29	Janssen Pharmaceuticals Inc	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2440001T3 (es)	2009-05-12	2014-01-27	Janssen Pharmaceuticals, Inc.	Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
ES2552455T3 (es)	2010-11-08	2015-11-30	Janssen Pharmaceuticals, Inc.	Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
CN103298809B (zh)	2010-11-08	2016-08-31	杨森制药公司	1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CA2814998C (en)	2010-11-08	2019-10-29	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
PL2727912T3 (pl) *	2011-06-30	2017-12-29	Toray Industries, Inc.	Kryształy pochodnej glicyny i ich zastosowanie farmaceutyczne
FR2981071B1 (fr) *	2011-10-10	2014-02-07	Centre Nat Rech Scient	Synthese versatile et stereospecifique d'acides amines gamma,delta-insatures par la reaction de wittig
JPWO2014051056A1 (ja) *	2012-09-28	2016-08-22	東レ株式会社	グリシン誘導体の結晶及びその医薬用途
JO3368B1 (ar)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
IL279202B2 (en)	2014-01-21	2023-09-01	Janssen Pharmaceutica Nv	Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use
US10537573B2 (en)	2014-01-21	2020-01-21	Janssen Pharmaceutica Nv	Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
WO2024073067A2 (en) *	2022-09-30	2024-04-04	Mayo Foundation For Medical Education And Research	Assessing and treating tremor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5235910A (en)	1992-07-07	1993-08-17	A. B. Dick Company	Blanket cylinder impression throw-off
CA2150550A1 (en)	1992-12-01	1994-06-09	Melissa S. Egbertson	Fibrinogen receptor antagonists
JPH10501222A (ja)	1994-05-27	1998-02-03	メルクエンドカンパニーインコーポレーテッド	破骨細胞仲介骨吸収を抑制するための化合物
WO1999026923A1 (en)	1997-11-20	1999-06-03	Merck & Co., Inc.	Para-aminomethylaryl carboxamide derivatives
PL207160B1 (pl) *	1999-12-06	2010-11-30	Hoffmann La Roche	Pochodne 4-pirymidynylo-N-acylo-L-fenyloalaniny, związki pośrednie, środek farmaceutyczny i ich zastosowanie
CN1325480C (zh) *	2000-08-18	2007-07-11	味之素株式会社	苯基丙氨酸衍生物
JP4452899B2 (ja) *	2001-12-13	2010-04-21	味の素株式会社	新規フェニルアラニン誘導体
EP1840121B1 (de)	2004-12-24	2012-08-29	Toray Industries, Inc.	Glycinderivate und deren verwendung

2007
- 2007-06-18 CA CA2655573A patent/CA2655573C/en not_active Expired - Fee Related
- 2007-06-18 AU AU2007262147A patent/AU2007262147B2/en not_active Ceased
- 2007-06-18 JP JP2008522446A patent/JP5228911B2/ja active Active
- 2007-06-18 ES ES07745470T patent/ES2384400T3/es active Active
- 2007-06-18 CN CN2007800226735A patent/CN101472900B/zh not_active Expired - Fee Related
- 2007-06-18 WO PCT/JP2007/062220 patent/WO2007148648A1/ja not_active Ceased
- 2007-06-18 AT AT07745470T patent/ATE556061T1/de active
- 2007-06-18 KR KR1020097000892A patent/KR101423347B1/ko not_active Expired - Fee Related
- 2007-06-18 EP EP07745470A patent/EP2039687B1/de not_active Not-in-force
- 2007-06-18 US US12/305,078 patent/US7879837B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR101423347B1 (ko)	2014-07-24
EP2039687B1 (de)	2012-05-02
WO2007148648A1 (ja)	2007-12-27
US20090275599A1 (en)	2009-11-05
KR20090031422A (ko)	2009-03-25
CN101472900B (zh)	2011-07-27
JPWO2007148648A1 (ja)	2009-11-19
AU2007262147B2 (en)	2012-08-16
US7879837B2 (en)	2011-02-01
JP5228911B2 (ja)	2013-07-03
ES2384400T3 (es)	2012-07-04
EP2039687A1 (de)	2009-03-25
AU2007262147A1 (en)	2007-12-27
CA2655573C (en)	2014-04-29
CA2655573A1 (en)	2007-12-27
CN101472900A (zh)	2009-07-01
EP2039687A4 (de)	2010-09-08

Publication	Publication Date	Title
ATE556061T1 (de)	2012-05-15	Therapeutisches oder prophylaktisches mittel gegen multiple sklerose
WO2006069155A3 (en)	2006-11-23	Inhibitors of protein arginine methyl transferases
EA201100795A1 (ru)	2012-01-30	Фармацевтическая композиция эффективного ингибитора всг для перорального введения
PL369108A1 (en)	2005-04-18	17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
NO20072515L (no)	2007-06-28	2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
CY2013023I1 (el)	2015-10-07	Φαρμακο για την υπερδραστηρια ουροδοχο κυστη περιλαμβανον παραγωγο ανιλιδιου οξικου οξεος ως το ενεργο συστατικο
IS8502A (is)	2006-06-08	Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
NO20043367L (no)	2004-08-13	Oralt farmasoytisk preparat
SE0402762D0 (sv)	2004-11-11	Indazole sulphonamide derivatives
WO2004071374A3 (en)	2004-12-16	Once a day orally administered pharmaceutical compositions
WO2009041787A3 (en)	2009-05-14	Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper nigrum for the prevention and treatment of inflammatory disease
EP1774968A4 (de)	2007-11-07	Benzylisochinolin-derivat oder bisbenzylisochinolin-derivat enthaltendes psychotropes mittel, analgetikum und/oder antiphlogistikum und nahrungsmittel zur förderung der gesundheit
MXPA05006889A (es)	2006-04-07	Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
DK1228758T3 (da)	2007-10-29	Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom
ATE497761T1 (de)	2011-02-15	Therapeutisches oder prophylaktisches mittel gegen leukämie
JP2003522768A5 (de)	2011-09-08
WO2007056142A3 (en)	2007-11-08	Methods of preventing the serotonin syndrome and compositions for use therefor
MXPA06003122A (es)	2006-05-31	Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos.
WO2009041786A3 (en)	2009-05-14	Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper longum for the prevention and treatment of inflammatory disease
WO2004048381A3 (en)	2004-08-05	Pyrazoloazepine compounds as pharmaceutical agents
ATE508741T1 (de)	2011-05-15	Therapeutisches oder prophylaktisches mittel gegen allergische dermatitis
JP2004512376A5 (de)	2005-08-18
WO2003070153A3 (en)	2003-12-24	Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives
WO2006031719A3 (en)	2006-09-14	1,4-bis-n-oxide-5,8-dihydroxyanthracenedione compounds and the use thereof
EP1747200B8 (de)	2010-09-08	Alkaloidverbindungen und ihre verwendung als antimalariamittel